US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
WO1995013796A1
(en)
|
1993-11-16 |
1995-05-26 |
Depotech Corporation |
Vesicles with controlled release of actives
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
EP0454781B1
(en)
|
1989-01-23 |
1998-12-16 |
Chiron Corporation |
Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
|
US5756747A
(en)
|
1989-02-27 |
1998-05-26 |
Riker Laboratories, Inc. |
1H-imidazo 4,5-c!quinolin-4-amines
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
EP0465529B1
(en)
|
1989-03-21 |
1998-04-29 |
Vical, Inc. |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
DE3920358A1
(en)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
|
WO1991002805A2
(en)
|
1989-08-18 |
1991-03-07 |
Viagene, Inc. |
Recombinant retroviruses delivering vector constructs to target cells
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
NZ237464A
(en)
|
1990-03-21 |
1995-02-24 |
Depotech Corp |
Liposomes with at least two separate chambers encapsulating two separate biologically active substances
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
ES2108048T3
(en)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
ES2113940T3
(en)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
JP4124480B2
(en)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
Immunoglobulin variants
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
ES2197145T3
(en)
|
1991-08-20 |
2004-01-01 |
The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services |
TRANSFER OF GENES MEDIATED BY ADENOVIRUS TO GASTROINTESTINAL.
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
AU665025B2
(en)
|
1991-09-23 |
1995-12-14 |
Cambridge Antibody Technology Limited |
Production of chimeric antibodies - a combinatorial approach
|
ES2136092T3
(en)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
WO1993010260A1
(en)
|
1991-11-21 |
1993-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
EP0617706B1
(en)
|
1991-11-25 |
2001-10-17 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
FR2688514A1
(en)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
WO1993025234A1
(en)
|
1992-06-08 |
1993-12-23 |
The Regents Of The University Of California |
Methods and compositions for targeting specific tissue
|
EP0644946A4
(en)
|
1992-06-10 |
1997-03-12 |
Us Health |
Vector particles resistant to inactivation by human serum.
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
EP0656064B1
(en)
|
1992-08-17 |
1997-03-05 |
Genentech, Inc. |
Bispecific immunoadhesins
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
AU680459B2
(en)
|
1992-12-03 |
1997-07-31 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
CA2161225C
(en)
|
1993-04-22 |
2003-07-01 |
Sinil Kim |
Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
JP3532566B2
(en)
|
1993-06-24 |
2004-05-31 |
エル. グラハム,フランク |
Adenovirus vectors for gene therapy
|
DE69425661T2
(en)
|
1993-07-15 |
2001-04-19 |
Minnesota Mining & Mfg |
IMIDAZO [4,5-c] PYRIDINE-4-AMINE
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
DE69433461T2
(en)
|
1993-09-15 |
2004-11-18 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Recombinant alphavirus vector
|
ES2328585T3
(en)
|
1993-10-25 |
2009-11-16 |
Canji, Inc. |
VENUE OF ADENOVIRUS RECOMBINANT AND METHOD OF USE.
|
US6436908B1
(en)
|
1995-05-30 |
2002-08-20 |
Duke University |
Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
|
AU2585395A
(en)
|
1994-05-09 |
1995-11-29 |
Chiron Corporation |
Retroviral vectors having a reduced recombination rate
|
EP1167377B2
(en)
|
1994-07-15 |
2012-08-08 |
University of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
EP0953052B1
(en)
|
1996-05-06 |
2009-03-04 |
Oxford BioMedica (UK) Limited |
Crossless retroviral vectors
|
US6028076A
(en)
|
1996-07-03 |
2000-02-22 |
Japan Energy Corporation |
Purine derivative
|
US6387938B1
(en)
|
1996-07-05 |
2002-05-14 |
Mochida Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
WO1998030562A1
(en)
|
1997-01-09 |
1998-07-16 |
Terumo Kabushiki Kaisha |
Novel amide derivatives and intermediates for the synthesis thereof
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
US6339068B1
(en)
|
1997-05-20 |
2002-01-15 |
University Of Iowa Research Foundation |
Vectors and methods for immunization or therapeutic protocols
|
EP0983303B1
(en)
*
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
AU9692198A
(en)
|
1997-10-10 |
1999-05-03 |
Kevin J. Donahue |
Gene delivery compositions and methods
|
EP1035123B1
(en)
|
1997-11-28 |
2003-08-20 |
Sumitomo Pharmaceuticals Company, Limited |
Novel heterocyclic compounds
|
UA67760C2
(en)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
|
TW572758B
(en)
|
1997-12-22 |
2004-01-21 |
Sumitomo Pharma |
Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
JP2000119271A
(en)
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h-imidazopyridine derivative
|
WO2000075304A1
(en)
|
1999-06-08 |
2000-12-14 |
Aventis Pasteur |
Immunostimulant oligonucleotide
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
KR100651294B1
(en)
|
1999-08-13 |
2006-11-28 |
이데라 파마슈티칼즈, 인코포레이티드 |
MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
CA2403553A1
(en)
|
2000-03-17 |
2001-09-27 |
David Johnson |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
US6651132B1
(en)
|
2000-07-17 |
2003-11-18 |
Microsoft Corporation |
System and method for emulating the operation of a translation look-aside buffer
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6677347B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
CN1604795B
(en)
|
2001-08-17 |
2010-05-26 |
科勒制药股份公司 |
Combination motif immune stimulatory oligonucleotides with improved activity
|
ATE448238T1
(en)
|
2001-11-27 |
2009-11-15 |
Anadys Pharmaceuticals Inc |
3-BETA-D-RIBOFURANOSYLTHIAZOLO(4,5-DELTA)PYRIDIMININE NUCLEOSIDES AND THEIR USE
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6525028B1
(en)
|
2002-02-04 |
2003-02-25 |
Corixa Corporation |
Immunoeffector compounds
|
NZ537054A
(en)
|
2002-06-07 |
2006-10-27 |
3M Innovative Properties Co |
Ether substituted imidazopyridines
|
JP4860923B2
(en)
|
2002-08-15 |
2012-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
Immunostimulatory composition and method of stimulating immune response
|
AR040996A1
(en)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
IMMUNE STIMULATING NUCLEIC ACIDS
|
AU2003299082A1
(en)
|
2002-09-26 |
2004-04-19 |
3M Innovative Properties Company |
1h-imidazo dimers
|
MXPA05006740A
(en)
|
2002-12-20 |
2005-10-05 |
3M Innovative Properties Co |
Aryl / hetaryl substituted imidazoquinolines.
|
US7449616B2
(en)
|
2002-12-24 |
2008-11-11 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
WO2004080398A2
(en)
|
2003-03-07 |
2004-09-23 |
3M Innovative Properties Company |
1-amino 1h-imidazoquinolines
|
ES2423800T3
(en)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
MXPA06001674A
(en)
|
2003-08-12 |
2006-05-12 |
3M Innovative Properties Co |
Hydroxylamine substituted imidazo-containing compounds.
|
KR101106812B1
(en)
|
2003-08-27 |
2012-01-19 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines
|
AR045563A1
(en)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
ANTIBODIES DIRECTED TO M-CSF
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
KR101494056B1
(en)
|
2003-10-03 |
2015-02-16 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
Pyrazolopyridines and analogs thereof
|
KR101154101B1
(en)
|
2003-10-03 |
2012-06-11 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
Alkoxy substituted imidazoquinolines
|
US8598192B2
(en)
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
JP2007511527A
(en)
|
2003-11-14 |
2007-05-10 |
スリーエム イノベイティブ プロパティズ カンパニー |
Oxime-substituted imidazo ring compounds
|
JP2007512349A
(en)
|
2003-11-25 |
2007-05-17 |
スリーエム イノベイティブ プロパティズ カンパニー |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
MXPA06005910A
(en)
|
2003-11-25 |
2006-08-23 |
3M Innovative Properties Co |
Substituted imidazo ring systems and methods.
|
EP1694674A4
(en)
|
2003-12-04 |
2010-07-07 |
3M Innovative Properties Co |
Sulfone substituted imidazo ring ethers
|
JP2007530450A
(en)
|
2003-12-29 |
2007-11-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
Piperazine, [1,4] diazepan, [1,4] diazocan, and [1,5] diazocan condensed imidazo ring compounds
|
WO2005066170A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
AU2004312508A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
AU2005228150A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
UA94211C2
(en)
*
|
2004-06-03 |
2011-04-26 |
Новиммюн С.А. |
Isolated fully human monoclonal anti-cd3 antibody
|
US20080015184A1
(en)
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
WO2006009826A1
(en)
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US7884207B2
(en)
|
2004-06-18 |
2011-02-08 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20070259881A1
(en)
|
2004-06-18 |
2007-11-08 |
Dellaria Joseph F Jr |
Substituted Imidazo Ring Systems and Methods
|
WO2006093514A2
(en)
|
2004-06-18 |
2006-09-08 |
3M Innovative Properties Company |
Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006029115A2
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
EP1789042B1
(en)
|
2004-09-02 |
2012-05-02 |
3M Innovative Properties Company |
1-alkoxy 1h-imidazo ring systems and methods
|
WO2006026760A2
(en)
|
2004-09-02 |
2006-03-09 |
3M Innovative Properties Company |
1-amino imidazo-containing compounds and methods
|
WO2006028451A1
(en)
|
2004-09-03 |
2006-03-16 |
3M Innovative Properties Company |
1-amino 1-h-imidazoquinolines
|
US7943609B2
(en)
|
2004-12-30 |
2011-05-17 |
3M Innovative Proprerties Company |
Chiral fused [1,2]imidazo[4,5-C] ring compounds
|
WO2006083440A2
(en)
|
2004-12-30 |
2006-08-10 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
JP5122980B2
(en)
|
2005-02-09 |
2013-01-16 |
スリーエム イノベイティブ プロパティズ カンパニー |
Alkyloxy-substituted thiazoloquinolines and alkyloxy-substituted thiazolonaphthylidenes
|
CA2597587A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
WO2006086633A2
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
|
AU2006216997A1
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
JP2008531567A
(en)
|
2005-02-23 |
2008-08-14 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
Hydroxyalkyl-substituted imidazoquinoline compounds and methods
|
US8178677B2
(en)
|
2005-02-23 |
2012-05-15 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
US8343993B2
(en)
|
2005-02-23 |
2013-01-01 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazonaphthyridines
|
CA2598437A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
EP1871417B1
(en)
|
2005-04-15 |
2013-09-11 |
Precision Biologics, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
US7791214B2
(en)
|
2006-10-10 |
2010-09-07 |
Adaptide, Inc. |
Adaptive tidal current power extraction device
|
EP2190440A1
(en)
|
2007-08-13 |
2010-06-02 |
Pfizer Inc. |
Combination motif immune stimulatory oligonucleotides with improved activity
|
SI2594590T1
(en)
|
2007-12-14 |
2015-03-31 |
Bristol-Myers Squibb Company |
Method of producing binding molecules for the human OX40 receptor
|
US8552165B2
(en)
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
WO2012059882A2
(en)
|
2010-11-05 |
2012-05-10 |
Rinat Neuroscience Corporation |
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
SA112330278B1
(en)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
Novel modulators and methods of use
|
SI2780039T1
(en)
|
2011-11-17 |
2018-06-29 |
Pfizer Inc. |
Cytotoxic peptides and antibody drug conjugates thereof
|
US10000567B2
(en)
*
|
2012-06-14 |
2018-06-19 |
Therapix Biosciences Ltd. |
Humanized antibodies to cluster of differentiation 3 (CD3)
|
EP3016681B1
(en)
*
|
2013-07-05 |
2019-12-18 |
Genmab A/S |
Humanized or chimeric cd3 antibodies
|
WO2015015448A2
(en)
|
2013-07-31 |
2015-02-05 |
Rinat Neuroscience Corp. |
Engineered polypeptide conjugates
|
SG11201603244VA
(en)
*
|
2013-11-04 |
2016-05-30 |
Glenmark Pharmaceuticals Sa |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
US9501570B2
(en)
|
2014-07-14 |
2016-11-22 |
Verizon Patent And Licensing Inc. |
Dynamic routing system
|
CA2955947A1
(en)
*
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
TWI595006B
(en)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
Anti-pd-1 antibodies and methods of use thereof
|
US9719791B2
(en)
|
2014-12-10 |
2017-08-01 |
Mapquest, Inc. |
Computerized systems and methods for providing travel information and/or content to users
|
TWI703157B
(en)
*
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Cd3-specific antibodies, therapeutic bispecific antibodies and their uses
|
EP3091032A1
(en)
*
|
2015-05-08 |
2016-11-09 |
Miltenyi Biotec GmbH |
Humanized antibody or fragment thereof specific for cd3
|
WO2016204966A1
(en)
*
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
US9914777B2
(en)
*
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
WO2018220584A1
(en)
|
2017-06-02 |
2018-12-06 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|